CLAIM CARD
The quantitative findings from Correia-Melo et al. demonstrate a mixed effect profile. Rapamycin significantly improved markers of frailty and healthspan, with multiple endpoints reaching statistical significance (P < 0.01, P < 0.001). Despite these functional improvements, the intervention did not impact the chronic inflammatory state (inflammaging) characteristic of the nfκb1 −/− model, nor did it alter overall survival. This suggests that rapamycin's benefits in this context may be mediated through mechanisms independent of direct lifespan extension or broad suppression of NF-κB-driven inflammation.
Evidence grade: exploratory
Contradiction status: none
Publication: 1ece772b-d3e4-4ad0-b090-ac7e9ea4a1d6
Provenance: Derivation Web chain
Citation Support
source_1Mandrioli 2023source_2Lin 2022source_3Moel 2025source_4Gkioni 2025source_5Zhou 2024